Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00770315
Other study ID # P05234
Secondary ID 38102492008-0038
Status Completed
Phase Phase 3
First received October 9, 2008
Last updated October 12, 2015
Start date September 2009
Est. completion date May 2011

Study information

Verified date October 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season.


Recruitment information / eligibility

Status Completed
Enrollment 784
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Must have a clinical history of significant ragweed-induced allergic rhinoconjunctivitis of at least 2 years duration, with or without asthma and have received treatment during the previous ragweed season (RS).

- Must have a positive skin prick test response to Ambrosia artemisiifolia at Screening Visit.

- Must be positive for specific immunoglobulin E (IgE) against Ambrosia artemisiifolia at Screening Visit.

- Must have an forced expiratory volume in one second (FEV1) of at least 70% of predicted at Screening Visit.

- Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor.

- Must be willing to give written informed consent and be able to adhere to dose and visit schedules.

- Female participants of childbearing potential must be using a medically acceptable and adequate form of birth control. These include: hormonal contraceptives as prescribed by a physician (oral, hormonal vaginal ring, hormonal implant or depot injectable); medically prescribed intra-uterine device; medically prescribed topically-applied transdermal contraceptive patch; double-barrier method (eg, condom in combination with a spermicide).

- Female participants of childbearing potential should be counseled in the appropriate use of birth control while in the study. Female participants who are not currently sexually active must and consent to use one of the above-mentioned methods if she becomes sexually active during the study.

- Female participants of childbearing potential must have a negative urine pregnancy test at Screening Visit. Women who have been surgically sterilized or at least 1 year postmenopausal are not considered to be of childbearing potential.

Exclusion Criteria:

- Clinical history of symptomatic seasonal allergic rhinitis and/or asthma having received regular medication, due to another during or potentially overlapping the RS.

- Clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed.

- Receipt of an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).

- Clinical history of severe asthma.

- Asthma requiring medium or high dose inhaled corticosteroids (ICS).

- History of anaphylaxis with cardiorespiratory symptoms.

- History of chronic urticaria and angioedema.

- Clinical history of chronic sinusitis 2 years prior to the Screening Visit.

- Current severe atopic dermatitis.

- Breast-feeding, pregnancy, or intending to become pregnant.

- Had previous treatment by immunotherapy with ragweed allergen or any other allergen 5 years prior to Screening Visit.

- History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (except for Ambrosia artemisiifolia), rescue medications, or self-injectable epinephrine.

- Any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.

- Use of any investigational drugs within 30 days of Screening Visit.

- Participation in any other clinical study.

- Being a family member of the study staff.

- Inability to meet medication washout requirements.

- Unlikely to be able to complete the trial, or likely to travel for an extended time during the RS.

- Clinically significant abnormal vital sign or lab value.

- Participation in this same study at another site.

- Randomized into this study more than once.

- Inability to or will not comply with the use of self-injectable epinephrine.

- Greater risk of developing adverse reactions after epinephrine administration.

- History of self-injectable epinephrine use

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
Placebo
Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nékám K, Nolte H. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013 May;131(5):1342- — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. The 15-day period during the ragweed season with the highest moving pollen average No
Secondary Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. Approximately 5 weeks No
Secondary Average Rhinoconjunctivitis DSS for the Peak RS The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. The 15-day period during the ragweed season with the highest moving pollen average No
Secondary Average Rhinoconjunctivitis DSS for the Entire RS The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. Approximately 5 weeks No
Secondary Average Rhinoconjunctivitis DMS for the Peak RS Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. The 15-day period during the ragweed season with the highest moving pollen average No
See also
  Status Clinical Trial Phase
Completed NCT02424539 - A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR) Phase 4
Completed NCT02486159 - The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture N/A
Completed NCT00771160 - MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED) Phase 3
Completed NCT00834119 - Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270) Phase 4
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Recruiting NCT05621356 - Monitoring Allergen Immunotherapy in Allergic Rhinitis
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT03758456 - HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human Phase 1
Completed NCT04645979 - A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
Completed NCT05122143 - Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers N/A
Completed NCT05901532 - Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis Phase 2
Terminated NCT02722083 - Exploratory Study for Allergy Relief Onset Phase 2
Recruiting NCT05656482 - Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Recruiting NCT04898283 - Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses. Phase 3
Recruiting NCT06436534 - Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis N/A
Recruiting NCT05922176 - Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
Completed NCT02679105 - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy Phase 2/Phase 3
Completed NCT01104012 - Validation of Proteomic Analyses for Allergic Asthma and Rhinitis N/A
Completed NCT03375775 - Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children N/A